Evidence map›Paper›PMID 36101851›Full record

ArticleInternational journal of health sciences

Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovići municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.

Amir Ibrahimagić, Senad Huseinagić, Selvedina Sarajlić-Spahić, Fatima Bašić, Jasmin Durmišević

Open access · greenAbstract read
In one paragraph

Article in International journal of health sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. International journal of health sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amir IbrahimagićDepartment for Chemical Diagnostics, Institute for Health and Food Safety, Fra Ivana Jukića 2, 72 000 Zenica, Bosnia and Herzegovina.
Senad HuseinagićManagement of Institute for Health and Food Safety, Fra Ivana Jukića 2, 72 000 Zenica, Bosnia and Herzegovina.
Selvedina Sarajlić-SpahićDepartment for Promotion and Quality in Health, Institute for Health and Food Safety, Fra Ivana Jukića 2, 72 000 Zenica, Bosnia and Herzegovina.
Fatima BašićDepartment for Epidemiology and Ecology, Institute for Health and Food Safety, Fra Ivana Jukića 2, 72 000 Zenica, Bosnia and Herzegovina.
Jasmin DurmiševićSection for Health Ecology and Hygiene, Institute for Health and Food Safety, Fra Ivana Jukića 2, 72 000 Zenica, Bosnia and Herzegovina.
University of Zenica · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Improved serological detection of specific antibodies against SARS-CoV-2 could help estimate the true number of infections. Methods: A total of 443 serum samples provided by unvaccinated patients of all ages with unknown COVID-19 status that were originally submitted for routine screening or clinical management from outpatient laboratory during the March-April 2021 (third wave) were collected. Seroprevalence of IgM/IgG antibodies was determined by lateral flow immunoassay (Tigsun, Beijing, China). Results: Among 443 serum samples, 186 (42.0%) were positive (incidence of 5.2/1000) with slight predominace of females, 104 (55.9%), highest seropositivity in 25-50 and 51-64 years age groups, 61 (32.8%) and 57 (30.6%), respectively ( Conclusion: In the regions with high prevalence/incidence of SARS-CoV-2 in the general population (Bosnia and Herzegovina is on the World top on the number of deaths) seroprevalence measuring can help tracking the spread of disease.

Indexed as

Comorbiditycoronavirusseroprevalencesymptoms

Identifiers

PMID36101851
PMCPMC9441649
OpenAlexW4295751312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.